Boundless Bio Inc
For the period ended Sep 30, 2024. Filed Nov 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 7, 2024
BOLD$2.46+2.1%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Balance Sheets
(in thousands, except share and par value data)
| September 30,2024 | December 31,2023 | |
|---|---|---|
| (unaudited) | ||
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $40,214 | $23,706 |
| Short-term investments | 126,921 | 97,046 |
| Prepaid expenses and other current assets | 3,314 | 3,452 |
| Total current assets | 170,449 | 124,204 |
| Property and equipment, net | 3,959 | 2,573 |
| Right-of-use asset, net | 109 | 2,002 |
| Restricted cash | 560 | 560 |
| Other assets | 16 | 555 |
| Total assets | $175,093 | $129,894 |
| Liabilities, convertible preferred stock, and stockholders’ equity / (deficit) | ||
| Current liabilities | ||
| Accounts payable and accrued liabilities | $7,041 | $4,266 |
| Accrued compensation | 2,848 | 2,898 |
| Lease liabilities, current portion | 121 | 2,195 |
| Total current liabilities | 10,010 | 9,359 |
| Commitments and contingencies (Note 8) | ||
| Convertible preferred stock, $0.0001 par value; no shares authorized, issued, or outstanding as of September 30, 2024; 287,446,844 shares authorized, issued, and outstanding as of December 31, 2023; liquidation preference of $252.1 million as of December 31, 2023 | — | 247,617 |
| Stockholders’ equity / (deficit): | ||
| Preferred stock, $0.0001 par value; 70,000,000 shares authorized and no shares issued and outstanding as of September 30, 2024; no shares authorized and no shares issued and outstanding as of December 31, 2023 | — | — |
| Common stock, $0.0001 par value; 700,000,000 shares authorized, 22,254,537 shares issued, and 22,254,465 shares outstanding as of September 30, 2024; 402,600,000 shares authorized, 1,248,493 shares issued, and 1,247,012 shares outstanding as of December 31, 2023 | 2 | — |
| Additional paid-in-capital | 349,869 | 8,987 |
| Accumulated other comprehensive income | 236 | 40 |
| Accumulated deficit | (185,024) | (136,109) |
| Total stockholders’ equity / (deficit) | 165,083 | (127,082) |
| Total liabilities, convertible preferred stock, and stockholders’ equity / (deficit) | $175,093 | $129,894 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.